FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2382808110> ?p ?o ?g. }

• W2382808110 endingPage "S388" @default.
• W2382808110 startingPage "S387.6" @default.
• W2382808110 abstract "Purpose Epstein-Barr virus (EBV) is a human tumor virus of the gamma-Herpes virus family and transforms B cells in vitro and in vivo. EBV establishes persistent infections in more than 90% of the adult population, and although most remain completely healthy, a small minority of infected individuals develops spontaneous EBV-associated malignancies (such as lymphoma, nasal-pharyngeal carcinoma, and post-transplant lymphoproliferative diseases). Its nuclear antigen 1 (EBNA1) is the only EBV protein expressed in all EBV associated malignancies. This study investigates the subtle differences in immune response to EBNA1 among healthy carriers in comparison to patients afflicted with EBV-associated malignancies. Methods All healthy volunteers and lymphoma patients were consented to provide peripheral blood samples according to our IRB-approved protocols. EBNA1 specific CD4+ T cells were detected by IFN-gamma production and proliferation upon stimulation with overlapping peptides covering the EBNA1400-641 sequence. In the first evaluation, ex vivo blood samples were immediately subjected to pools of overlapping peptides of EBNA1, followed by intracellular cytokine staining and flow cytometry to quantify and phenotype all EBNA1 specific CD4+ T cells. Peripheral blood mono-nuclear cells (PBMCs) stained with carboxyfluorescein succinimidyl ester (CFSE) and were tested for proliferation (CFSE dilution) in response to the same pools of overlapping peptides of EBNA1. Results We have determined the frequency and surface marker phenotype of EBNA1 specific CD4+ T cells in peripheral blood of healthy EBV carriers. Healthy carriers (17/19) had detectable CD4+ T cell responses to EBNA1. EBNA1 specific CD4+ T cells were primarily CD45RO+CD45RA-CD27+CD28+ and contained both CD62L+ and CD62L- subpopulations. Although lymphoma patients with EBV-negative tumors had detectable “healthy” EBNA1-specific CD4+ T cell responses (n = 4), none of the patients with EBV-positive lymphomas (n = 4) exhibited a “healthy” EBNA1-specific CD4+ T cell response. Conclusions Among healthy carriers, an average of 0.03% of CD4+ T cells are EBNA1-specific, however, such cells seem to be absent in patients with EBV-positive tumors. EBNA1 specific CD4+ T cells display a similar phenotype as latent EBV antigen specific CD8+ T cells. The continued study of the CD4+ T cell response to EBNA1 may reveal novel targets for therapies of EBV-associated malignancies." @default.
• W2382808110 created "2016-06-24" @default.
• W2382808110 creator A5016428520 @default.
• W2382808110 creator A5043606695 @default.
• W2382808110 creator A5074250377 @default.
• W2382808110 creator A5083026024 @default.
• W2382808110 creator A5084915056 @default.
• W2382808110 date "2005-03-01" @default.
• W2382808110 modified "2023-10-14" @default.
• W2382808110 title "6 EVALUATION OF THE CLINICAL SIGNIFICANCE OF EPSTEIN-BARR VIRUS (EBV)-SPECIFIC IMMUNITY AMONG HEALTHY EBV CARRIERS AND PATIENTS WITH EBV-ASSOCIATED MALIGNANCIES" @default.
• W2382808110 doi "https://doi.org/10.2310/6650.2005.00205.5" @default.
• W2382808110 hasPublicationYear "2005" @default.
• W2382808110 type Work @default.
• W2382808110 sameAs 2382808110 @default.
• W2382808110 citedByCount "0" @default.
• W2382808110 crossrefType "journal-article" @default.
• W2382808110 hasAuthorship W2382808110A5016428520 @default.
• W2382808110 hasAuthorship W2382808110A5043606695 @default.
• W2382808110 hasAuthorship W2382808110A5074250377 @default.
• W2382808110 hasAuthorship W2382808110A5083026024 @default.
• W2382808110 hasAuthorship W2382808110A5084915056 @default.
• W2382808110 hasConcept C142724271 @default.
• W2382808110 hasConcept C159047783 @default.
• W2382808110 hasConcept C203014093 @default.
• W2382808110 hasConcept C2522874641 @default.
• W2382808110 hasConcept C2779341262 @default.
• W2382808110 hasConcept C2780494569 @default.
• W2382808110 hasConcept C2781375147 @default.
• W2382808110 hasConcept C63363279 @default.
• W2382808110 hasConcept C71924100 @default.
• W2382808110 hasConcept C8891405 @default.
• W2382808110 hasConceptScore W2382808110C142724271 @default.
• W2382808110 hasConceptScore W2382808110C159047783 @default.
• W2382808110 hasConceptScore W2382808110C203014093 @default.
• W2382808110 hasConceptScore W2382808110C2522874641 @default.
• W2382808110 hasConceptScore W2382808110C2779341262 @default.
• W2382808110 hasConceptScore W2382808110C2780494569 @default.
• W2382808110 hasConceptScore W2382808110C2781375147 @default.
• W2382808110 hasConceptScore W2382808110C63363279 @default.
• W2382808110 hasConceptScore W2382808110C71924100 @default.
• W2382808110 hasConceptScore W2382808110C8891405 @default.
• W2382808110 hasIssue "2" @default.
• W2382808110 hasLocation W23828081101 @default.
• W2382808110 hasOpenAccess W2382808110 @default.
• W2382808110 hasPrimaryLocation W23828081101 @default.
• W2382808110 hasRelatedWork W1964985474 @default.
• W2382808110 hasRelatedWork W2009749110 @default.
• W2382808110 hasRelatedWork W2013586951 @default.
• W2382808110 hasRelatedWork W2017428364 @default.
• W2382808110 hasRelatedWork W2030238129 @default.
• W2382808110 hasRelatedWork W2064724845 @default.
• W2382808110 hasRelatedWork W2095010252 @default.
• W2382808110 hasRelatedWork W2121615812 @default.
• W2382808110 hasRelatedWork W2141505157 @default.
• W2382808110 hasRelatedWork W2168911910 @default.
• W2382808110 hasVolume "53" @default.
• W2382808110 isParatext "false" @default.
• W2382808110 isRetracted "false" @default.
• W2382808110 magId "2382808110" @default.
• W2382808110 workType "article" @default.